AMD Treatment with VEGF Antagonist Dosing at 8 or 12 Weeks

USPTO published patent application US20260098085A1 for methods of treating age-related macular degeneration using VEGF antagonists administered on extended dosing schedules of 8 and/or 12 weeks. The application covers therapeutic methods intended to reduce patient treatment burden compared to more frequent dosing regimens. CPC classifications indicate the invention relates to immunological active ingredients, specifically antibodies classified under C07K 16/22.

For pharmaceutical and biotechnology companies developing ophthalmic therapeutics, this published application represents potential prior art for future patent filings in the VEGF antagonist space for ocular applications. Companies pursuing similar anti-VEGF therapies for AMD should review the claims for potential overlap with their own R&D programs. The publication date of April 9, 2026 establishes prior art status as of that date.